CoChat

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial

Open access
Holman, Rury R., Bethel, Mary Angelyn, George, Jyothis, Sourij, Harald, Doran, Zoë, Keenan, Joanne, Khurmi, Nardev S., Mentz, Robert J., Oulhaj, Abderrahim, Buse, John B., Chan, Juliana C., Iqbal, Nayyar, Kundu, Sudeep, Maggioni, Aldo P., Marso, Steven P., Öhman, Peter, Pencina, Michael J., Poulter, Neil, Porter, Lisa E., Ramachandran, Ambady, Zinman, Bernard, Hernandez, Adrian F. · 2016 · American Heart Journal
Cited by 108

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Exenatide once-weekly is an extended release formulation of exenatide, a glucagon-like peptide-1 receptor agonist, which can improve glycemic control, body weight, blood pressure, and lipid levels in patients with type 2 diabetes mellitus (T2DM). The EXenatide Study of Cardiovascular Event Lowering (EXSCEL) will compare the impact of adding exenatide once-weekly to usual care with usual care alone on major cardiovascular outcomes. EXSCEL is an academically led, phase III/IV, double-blind, pragmatic placebo-controlled, global trial conducted in 35 countries aiming to enrol 14,000 patients with T2DM and a broad range of cardiovascular risk over approximately 5 years. Participants will be randomized (1:1) to receive exenatide once-weekly 2 mg or matching placebo by subcutaneous injections. The trial will continue until 1,360 confirmed primary composite cardiovascular end points, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, have occurred. The primary efficacy hypothesis is that exenatide once-weekly is superior to usual care with respect to the primary composite cardiovascular end point. EXSCEL is powered to detect a 15% relative risk reduction in the exenatide once-weekly group, with 85% power and a 2-sided 5% alpha. The primary safety hypothesis is that exenatide once-weekly is noninferior to usual care with respect to the primary cardiovascular composite end point. Noninferiority will be concluded if the upper limit of the CI is <1.30. EXSCEL will assess whether exenatide once-weekly can reduce cardiovascular events in patients with T2DM with a broad range of cardiovascular risk. It will also provide long-term safety information on exenatide once-weekly in people with T2DM. ClinicalTrials.gov Identifier: NCT01144338.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2015.12.009

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 108

Metadata

Authors
Holman, R. R., Bethel, M. A., George, J., Sourij, H., Doran, Z., Keenan, J., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., Chan, J. C., Iqbal, N., Kundu, S., Maggioni, A. P., Marso, S. P., Öhman, P., Pencina, M. J., Poulter, N., Porter, L. E., Ramachandran, A., Zinman, B., & Hernandez, A. F.
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2016-04
Volume
174
Pages
103-110
ISSN
0002-8703 (ISSN-L)
OpenAlex
W2200208573
Cited by
108
References
19
FWCI
11.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. https://app.cochat.ai/papers/10.1016/j.ahj.2015.12.009
The paper
Holman, R. R., Bethel, M. A., George, J., Sourij, H., Doran, Z., Keenan, J., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., Chan, J. C., Iqbal, N., Kundu, S., Maggioni, A. P., Marso, S. P., Öhman, P., Pencina, M. J., Poulter, N., Porter, L. E., . . . Hernandez, A. F. (2016). Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. American Heart Journal. https://doi.org/10.1016/j.ahj.2015.12.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.